Retention Samples | BA | BE | FDA Inspection | Regulatory Doctor

Regulations (21 CFR 320.38 and 320.63) for Retention Samples.  

The Division of Scientific Investigations (DSI) and FDA field investigators conduct inspections of clinical and analytical sites that perform bioavailability (BA) and bioequivalence (BE) testing for drug manufacturers seeking approval of a drug product. One of the most common findings from these inspections is the absence of retention samples by the testing facility where the study was conducted. The regulations regarding retention samples of test articles can be found in 21 CFR 320.38 and 320.63. The final rule on these regulations can be found in the Federal Register Notice, Vol. 58, No. 80, April 28, 1993.

via About the Center for Drug Evaluation and Research > Retention Samples.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s